Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2006, for Bioanalytical Systems, Inc. (BASi). The company operates in two principal segments: Research Services (providing contract R&D support to pharmaceutical companies) and Research Products (manufacturing scientific instruments for medical research). The filing notes that the company's performance is heavily dependent on pharmaceutical and biotech industry drug discovery efforts.
Key Financial Metrics
| Metric | Q1 2007 (Ended Dec 31, 2006) | Q1 2006 (Ended Dec 31, 2005) |
|---|---|---|
| Total Revenue | $10,884 | $9,844 |
| Gross Profit | $3,385 | $3,146 |
| Operating Income | $729 | $(913) |
| Net Income | $556 | $(716) |
| Diluted EPS | $0.11 | $(0.15) |
| Cash and Equivalents | $1,863 | $680 |
| Operating Cash Flow | $1,157 | $(339) |
| Total Debt (Current + Long-Term) | $10,941 | N/A |
Note: All figures in thousands except per share data. Total debt includes current portion of capital lease ($481), current portion of long-term debt ($844), long-term debt ($8,093), and subordinated debt ($3,999).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $1,040 (11%) year-over-year. Service revenue grew 25% ($1.0M increase) driven by bioanalytical and toxicology services, partially offset by a 33% decline in the Baltimore clinical research unit due to the loss of a significant customer.
- Profitability Turnaround: The company reported a net income of $556 compared to a net loss of $716 in the prior year. Operating income swung from a loss of $913 to a profit of $729.
- Expense Reduction: General and administrative expenses dropped 44% (from $2,887 to $1,622) due to personnel reductions in September 2006, reduced amortization from a prior impairment charge, and a shift to "as needed" staffing in Baltimore.
- Margin Dynamics: Service gross margin improved as a percentage of sales (costs decreased to 76.9% from 77.8%) due to fixed cost leverage. Product gross margin declined (costs increased to 38.5% from 36.3%) due to reduced manufacturing volume and unabsorbed costs.
Outlook, Risks, and Contingencies
- Capital Requirements: The company expects capital additions for fiscal 2007 to range between $1,000 and $1,200, funded by operating cash flow. It does not foresee a need to borrow extensively unless rapid growth necessitates working capital buildup.
- Debt Maturity Risk: Subordinated notes totaling $3,999 from a 2003 acquisition become due in January 2008. Management is currently exploring alternatives to fund this obligation.
- Liquidity: As of December 31, 2006, the company held $1,863 in cash and had $1,760 available under a $6,000 revolving credit facility (which expires December 31, 2007). A $2,000 letter of credit securing the Baltimore lease reduces available borrowing capacity.
- Market Risks: Primary exposures are interest rate fluctuations (revolving credit is floating) and foreign currency exchange rates. Management estimates a 10% adverse change in either would not materially affect operating results.
- Unusual Items: A $325 cost accrual was included in the quarter for repeating a study, which impacted margins. Additionally, the company utilized net operating loss carryforwards to offset foreign earnings tax.
Investor Verification Checklist
- Verify the status of funding alternatives for the $3,999 subordinated debt due in January 2008.
- Monitor the recovery trajectory of the Baltimore clinical research unit following the loss of a significant customer.
- Assess the sustainability of the 44% reduction in G&A expenses and whether further cost-cutting measures are required.
- Review the product segment margins to determine if reduced manufacturing volume will continue to pressure profitability.
- Confirm compliance with financial covenants in the revolving credit agreement, specifically regarding interest-bearing indebtedness to EBITDA ratios.